Janssen-Cilag asks EU's CHMP to re-consider Zeftera
This article was originally published in Scrip
Executive Summary
Janssen-Cilag (Johnson & Johnson) has requested a re-examination of the negative opinion adopted by the EU's CHMP for the filing of Basilea Pharmaceutica's antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and soft tissue infections.